1051931-39-5 Usage
Description
ZLJ-6 is a potent dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO) enzymes, with effective inhibitory concentrations (IC50) of 0.73, 0.31, and 0.99 μM for COX-1, COX-2, and 5-LO, respectively, in whole blood. It is known for its ability to alleviate inflammation and pain without causing gastrointestinal ulcers, which is a common side effect associated with non-selective COX inhibitors.
Uses
Used in Pharmaceutical Industry:
ZLJ-6 is used as an anti-inflammatory agent for its ability to reduce carrageenin-induced paw edema in rats, making it a potential candidate for treating various inflammatory conditions.
ZLJ-6 is also used as an analgesic agent for its effectiveness in mitigating acetic acid-induced abdominal constriction in mice, indicating its potential use in managing pain.
Additionally, ZLJ-6 is used as a gastrointestinal safety agent due to its lack of causing gastrointestinal ulcers, which is a significant advantage over non-selective COX inhibitors.
Used in Research and Development:
ZLJ-6 serves as a valuable compound in the development of new drugs targeting COX and 5-LO enzymes, contributing to the advancement of treatments for inflammation and pain management.
in vitro
zlj-6 was identified as a potent inhibitor of cyclooxygenase in human whole blood. it also inhibited the production of thromboxane b(2) and prostaglandin e(2) in calcium ionophore a23187-induced human and rat whole blood, and rat peritoneal leukocytes. zlj-6 suppressed the activity of 5-lipoxygenase in the rat basophilic leukemia (rbl-1) cell lysate and in intact cells and reduced the generation of leukotriene b(4) (ltb(4)) in a23187-stimulated human or rat whole blood, and rat peritoneal leukocytes [1].
in vivo
orally administered zlj-6 demonstrated potent anti-inflammatory activity in the carrageenin-induced paw oedema model in rats and showed analgesic activity in the acetic acid-induced abdominal construction model in mice. no gastrointestinal ulcers were found with the anti-inflammatory dose (30 mg/kg) in normal rats [1].
IC 50
0.73, 0.31, and 0.99 μm for cox-1, cox-2, and 5-lo, respectively
references
[1] li, l. ,ji, h.,sheng, l., et al. the anti-inflammatory effects of zlj-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. european journal of pharmacology 607 (1-3), 244-250 (2009).
Check Digit Verification of cas no
The CAS Registry Mumber 1051931-39-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,1,9,3 and 1 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1051931-39:
(9*1)+(8*0)+(7*5)+(6*1)+(5*9)+(4*3)+(3*1)+(2*3)+(1*9)=125
125 % 10 = 5
So 1051931-39-5 is a valid CAS Registry Number.
